Potassium News and Research

RSS

Research shows potatoes can be part of weight loss regimen

Research just released by the University of California, Davis and the National Center for Food Safety and Technology, Illinois Institute of Technology demonstrates that people can include potatoes in their diet and still lose weight. This research was presented at the Obesity Society's 28th Annual Scientific Meeting October 8-12, 2010.

12 Oct 2010

Essentialis receives patent for active component in DCCR product

Essentialis, Inc. announced today that the United States Patent & Trademark Office (USPTO) has issued U.S. Patent No. 7,799,777 entitled Salts of potassium ATP channel openers and uses thereof. The patent claims a novel composition of a polymorph of diazoxide choline, the active ingredient in the Essentialis lead product, DCCR. Essentialis has successfully completed phase 2b clinical trials with DCCR, showing a highly significant triglyceride reduction in dyslipidemic patients.

12 Oct 2010

ANDA approved for Losartan Potassium Tablets USP, Losartan Potassium and Hydrochlorothiazide Tablets

Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application for Losartan Potassium Tablets USP, 25mg, 50mg and 100mg as well as Losartan Potassium and Hydrochlorothiazide Tablets, 50mg/12.5mg and 100mg/25mg by the U.S. Food and Drug Administration. Both products are available for immediate shipment to wholesalers and pharmacies nationwide.

7 Oct 2010

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, and Mission Pharmacal Company, a privately-held pharmaceutical company focused on the women's health market announced today their exclusive co-promotion agreement for CAMBIA (diclofenac potassium for oral solution) to obstetrician's, gynecologists and other women's health medical professionals.

6 Oct 2010

Benicar better than Cozaar in reducing blood pressure: Study

New study results show that patients treated with Benicar® (olmesartan medoxomil) 40 mg once daily had significantly greater reductions in blood pressure and higher rates of goal attainment than patients receiving Cozaar® (losartan potassium) 100 mg once daily at week 8, according to findings of a new head-to-head study presented today at the late breaker session at the 23rd Scientific Meeting of the International Society of Hypertension (ISH) in Vancouver, Canada.

1 Oct 2010

Bayer’s new oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved a new oral contraceptive, Beyaz (drospirenone / ethinyl estradiol / levomefolate calcium tablets and levomefolate calcium tablets).

28 Sep 2010

Researchers find no link between dialysis treatments and cardiac symptoms

Dialysis treatments do not affect the heart health of kidney disease patients who have had a heart attack, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Since cardiovascular disease is the most common cause of death in kidney disease patients, the findings are good news for individuals who need the treatments.

27 Sep 2010

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.

16 Sep 2010

K-V secures $20 million loan from U.S. Healthcare

K-V Pharmaceutical Company announced today that it has entered into an agreement with U.S. Healthcare I, L.L.C. and U.S. Healthcare II, L.L.C. for a $20 million loan secured by assets of the Company. K-V will utilize the proceeds of the loan for working capital and general operating purposes.

15 Sep 2010

Potassium salt intake can improve blood pressure: Study

An increased intake of 'good' potassium salts could contribute significantly to improving blood pressure at the population level. The favourable effect brought about by potassium is even estimated to be comparable with the blood pressure reduction achievable by halving the intake of 'bad' sodium salts (mostly from table salt).

14 Sep 2010

Relypsa completes $70M Series B financing

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced the completion of a Series B financing totaling $70 million. OrbiMed Advisors, LLC, led the financing with participation from existing Relypsa investors New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout Group and Mediphase Venture Partners.

13 Sep 2010

Scientists find low levels of bacteria in fields sprayed with swine manure

That swine manure sprayed on to fields adds valuable nutrients to the soil is well known. But what is not known is whether all that manure is bringing harmful bacteria with it.

13 Sep 2010

K-V successfully completes FDA inspection for resumption of manufacturing and shipment of products

K-V Pharmaceutical Company announced today that it has received notice from the U.S. Food and Drug Administration ("FDA") of the successful completion of an inspection of the Company's facilities and approval to return its first product to market. Under the Company's Consent Decree, successful FDA inspections of the Company's quality systems, processes and facilities are expected to be required before K-V is permitted to resume manufacturing and shipment of particular products.

10 Sep 2010

Energy drink consumption can improve performance in young sports people: Study

Consuming energy drinks during team sports could help young people perform better, a study suggests. Sports scientists found that 12-14 year olds can play for longer in team games when they drink an isotonic sports drink before and during games.

9 Sep 2010

Researchers identify two proteins in cellular response to mechanical stimulation

Scripps Research Institute scientists have identified two proteins with potential to be important targets for research into a wide range of health problems, including pain, deafness, and cardiac and kidney dysfunction.

3 Sep 2010

Researchers discover new class of edible nanostructures for energy storage

Sugar, salt, alcohol and a little serendipity led a Northwestern University research team to discover a new class of nanostructures that could be used for gas storage and food and medical technologies. And the compounds are edible.

3 Sep 2010

DASH eating plan reduces long-term risk of heart attack among African-Americans: Study

The DASH eating plan, known to reduce blood pressure and bad cholesterol, also reduces the 10-year risk of heart attack, especially among African-Americans, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

2 Sep 2010

Moderate consumption of coffee benefits aortic distensibility in hypertensive elderly individuals

A detailed study conducted by a team from the University of Athens on the Aegean island of Ikaria has demonstrated that moderate consumption of coffee by hypertensive elderly individuals can lead to improvements in aortic distensibility. Distensibility is a measure of the elasticity of arteries, and low levels have long been recognised as an indicator of atherosclerosis and a reliable predictor of future cardiovascular events.

2 Sep 2010

RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients

Results from a recent phase 2b clinical trial may provide a new approach to managing excess potassium levels in patients with heart failure and heart failure with chronic kidney disease.

30 Aug 2010